If further data reveal that GLP1-RA combination therapy is more effective in reducing UACR than GLP1-RA monotherapy or insulin therapy, GLP1-RA combination therapy could be the first line of glycemic control and renoprotection in diabetic patients at risk of progression to CKD. This evidence concerns the gene GLP1R and chronic kidney disease.